In an era where cybersecurity is more critical than ever, DRP has become a vital technology for organizations aiming to protect their digital assets, prevent cyber threats, and manage online risks.

Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.

If you own shares in ASX companies that pay dividends, you have several options for using this new source of income. You can spend it straight away, add it to your holiday or emergency savings, or ...